Menu Search
Equities

Arecor Therapeutics PLC

AREC:LSE

Arecor Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)76.00
  • Today's Change-0.50 / -0.65%
  • Shares traded57.00
  • 1 Year change-59.14%
  • Beta0.1923
Data delayed at least 20 minutes, as of Nov 22 2024 11:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Arecor Therapeutics PLC grew revenues 90.30% from 2.40m to 4.57m while net income improved from a loss of 9.26m to a smaller loss of 8.55m.
Gross margin--
Net profit margin-176.89%
Operating margin-184.81%
Return on assets-56.84%
Return on equity-94.76%
Return on investment-89.06%
More ▼

Cash flow in GBPView more

In 2023, Arecor Therapeutics PLC increased its cash reserves by 6.88%, or 328.00k. Cash Flow from Investing totalled 6.52m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.84m for operations while cash used for financing totalled 180.00k.
Cash flow per share-0.2692
Price/Cash flow per share--
Book value per share0.1658
Tangible book value per share0.0604
More ▼

Balance sheet in GBPView more

Arecor Therapeutics PLC has a Debt to Total Capital ratio of 5.23%, a higher figure than the previous year's 0.39%.
Current ratio1.37
Quick ratio1.27
Total debt/total equity0.0551
Total debt/total capital0.0523
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.